valeant pharmaceuticals inte
(VRX:Toronto)

Financial Statements for valeant pharmaceuticals inte (VRX)

Currency in Millions of US Dollars	As of:	Dec 31 2009 Restated	Dec 31 2010 Reclassified	Dec 31 2011 Restated	Dec 31 2012	4 Year Trend
Revenues		820.4	1,181.2	2,463.5	3,546.6
TOTAL REVENUES		820.4	1,181.2	2,463.5	3,546.6
Cost of Goods Sold		218.2	352.1	667.6	959.7
GROSS PROFIT		602.3	829.2	1,795.9	2,586.9
Selling General & Admin Expenses, Total		167.6	256.4	572.5	756.1
R&D Expenses		47.6	67.9	65.7	79.1
Depreciation & Amortization, Total		104.7	219.8	517.3	852.8
Other Operating Expenses		--	89.2	4.0	15.5
OTHER OPERATING EXPENSES, TOTAL		319.9	633.4	1,159.5	1,703.4
OPERATING INCOME		282.3	195.8	636.4	883.5
Interest Expense		-25.4	-90.1	-334.5	-481.6
Interest and Investment Income		1.1	1.3	4.1	6.0
NET INTEREST EXPENSE		-24.3	-88.8	-330.4	-475.6
Currency Exchange Gains (Loss)		0.5	0.6	--	29.4
Other Non-Operating Income (Expenses)		--	--	7.5	-9.7
EBT, EXCLUDING UNUSUAL ITEMS		258.5	107.6	313.4	427.6
Merger & Restructuring Charges		-35.6	-253.3	-170.8	-501.8
Impairment of Goodwill		--	--	--	-12.8
Gain (Loss) on Sale of Investments		17.6	-5.6	22.8	2.1
Other Unusual Items, Total		-65.5	-85.0	-183.4	-309.3
In Process R&D Expenses		-59.4	--	--	--
Legal Settlements		-6.2	-52.6	-11.8	-56.8
Other Unusual Items		--	-32.4	-25.9	-26.8
EBT, INCLUDING UNUSUAL ITEMS		175.0	-236.3	-18.0	-394.2
Income Tax Expense		-1.5	-28.1	-177.6	-278.2
Earnings from Continuing Operations		176.5	-208.2	159.6	-116.0
NET INCOME		176.5	-208.2	159.6	-116.0
NET INCOME TO COMMON INCLUDING EXTRA ITEMS		176.5	-208.2	159.6	-116.0
NET INCOME TO COMMON EXCLUDING EXTRA ITEMS		176.5	-208.2	159.6	-116.0

Report Data Issue

To contact VALEANT PHARMACEUTICALS INTE, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.